Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taurolidine Lock Solution for CVC Infection Prevention in ICU
NCT07366372Completed
- Sponsor
- Tanta University
- Start
- May 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of taurolidine in Central venous catheter infection (CLABSI) (3 arms), sponsored by Tanta University. Primary endpoint: Positive bacterial growth at 30 days. Started May 2023; status: completed.
02
Drugs
taurolidine
03
Conditions
Central venous catheter infection (CLABSI)
Beyond the preview
Go deeper on NCT07366372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07366372.